Heparin recall spreads in Europe

In what seems to be a daily occurrence, more countries are announcing heparin recalls. France, Italy, and Denmark recalled the blood thinner or its ingredients. What's more, the Italian recall implicates a Chinese company supplying APP Pharmaceuticals, the only company still distributing large-dose heparin for surgery and dialysis in the U.S. after Baxter recalled its heparin products and stopped making them pending investigation.

The Italian company Opocrin said it had bought contaminated ingredient from Shenzhen Hepalink, APP's supplier. APP, however, says that Opocrin's active ingredient came from different slaughterhouses than APP's has. Plus, APP's heparin has proved contaminant-free in its own and FDA testing.

There have been no reports of adverse reactions in any of the three countries, but some batches of heparin and its active ingredient have proven contaminated or are suspected to be contaminated, according to a spokesman from the European Medicines Agency. "We presume it is the same contaminant" as the oversulfated chondroitin sulfate found in batches in the U.S., the spokesman said. Several dozen patients in Germany reported allergic reactions, and severe adverse effects were seen in hundreds in the U.S. Nineteen heparin patients have died. The FDA's investigation is ongoing.

- get the news from the New York Times
- read more in the Wall Street Journal

ALSO: A trial lawyer gives his view of the heparin news in a Q&A with Pharmalot. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.